Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tisenc Medical Raises $12 Million for Point-of-Care Chemiluminescence Testing

publication date: Jan 15, 2020

Shenzhen Tisenc Medical Equipment, a China point-of-care testing company, completed a $12 million Series B round led by Feifan Shulian and Taifu Capital. Founded in 2015, Tisenc is a China-foreign JV that offers single-use point-of-care automatic chemiluminescence (CLIA) analyzers and more than 100 matching in vitro diagnostic reagents. The company says its innovative ACCRE system can serve in emergency departments, STAT laboratories and core laboratories. Tisenc will use the proceeds of the funding to advance its R&D, increase production capacity and expand global marketing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China